Latest Lead News

CONNEQT Health has raised $3.1 million through an institutional placement to fuel growth of its Pulse vascular health device, supported by both new and existing investors including its largest shareholder.

Silver Mines Limited reports promising results from a recent drilling program at its Tuena Project, revealing significant gold and base metal mineralisation along a key fault corridor in New South Wales.

Reece Limited has increased its on-market share buyback target by $50 million, raising the total to $85 million as part of its disciplined capital management strategy.

Artemis Resources has secured a joint venture to earn a 60% stake in the Sharon Dam IOCG copper target, backed by a $220k government grant and planned drilling in early 2026. This deal extends Artemis’ footprint in a promising underexplored copper province in Western Australia.

Finbar Group has conditionally acquired a prime South Perth site for $16.5 million, aiming to launch a $350 million apartment development by 2028 and boosting its pipeline to over $1.6 billion.

Beetaloo Energy’s Carpentaria-5H well has delivered one of the highest gas flow rates in the Beetaloo Basin, showcasing promising long-term productivity and paving the way for pilot gas sales in 2026.

Viridis Mining and Minerals has achieved a critical environmental milestone with the granting of the Preliminary License for its Colossus Rare Earth Project in Brazil, significantly de-risking the development timeline and paving the way for construction in 2026.

Regis Healthcare announces the resignation of CEO Dr Linda Mellors after six years, with a transition period underway as the board searches for her successor.

Cann Group Limited has launched a comprehensive suite of option offers aimed at raising incremental capital, subject to shareholder approval at a December 23 meeting. The prospectus outlines potential dilution and financial impacts as the company seeks to strengthen its balance sheet.

Cyclopharm Limited has secured regulatory approval for its Technegas lung imaging technology in Colombia, marking its presence in 67 countries worldwide. This milestone aligns strategically with the upcoming global nuclear medicine congress in Cartagena.

Clarity Pharmaceuticals has secured positive FDA guidance to initiate a pivotal Phase III trial of its Cu-64 SARTATE diagnostic agent for neuroendocrine tumours, aiming to improve detection and patient outcomes.

Stockland has announced an estimated ordinary dividend of AUD 0.09 per security for the six months ending December 2025, payable in February 2026, alongside a Dividend Reinvestment Plan offering a 1% discount.